Tesamorelin Injection 2 Mg is a synthetic peptide designed to stimulate the natural release of growth hormone by acting on the pituitary gland. It is structurally similar to growth hormone–releasing hormone (GHRH) and is widely recognized in clRead More
Strength:
2 Mg
Active Ingredient:
Tesamorelin Acetate
Drug Class:
Growth Hormone Releasing Hormone Analogue
Product Type:
Injectable Peptide
Tesamorelin Injection 2 Mg is a synthetic peptide designed to stimulate the natural release of growth hormone by acting on the pituitary gland. It is structurally similar to growth hormone–releasing hormone (GHRH) and is widely recognized in clinical and research settings for its targeted action on growth hormone regulation. This injectable formulation is known for supporting metabolic balance and body composition by promoting the body’s own physiological pathways rather than supplying external hormones. Tesamorelin is commonly associated with applications related to fat metabolism, particularly in managing excess visceral fat, while helping preserve lean muscle mass.
Key Features
| Strength | 2 mg |
| Active Ingredient | Tesamorelin acetate |
| Drug Class | Growth hormone releasing hormone analogue |
| Product Type | Injectable peptide |
| Molecular Weight | 5135 Da |
| Primary Function | Stimulates HGH secretion |
| Mechanism | Activates GHRH receptors |
| Target System | Endocrine system |
| Administration | Subcutaneous injection |
| Dosage Form | Injectable solution |
| Frequency | Daily injection |
| Formulation | Prefilled syringe or vial |
| Storage | 2–8°C |
| Shelf Life | 24 months |
| Packaging | Sterile injection vial |
| Appearance | Clear or lyophilized powder |
| Stability | Sensitive to heat |
| Application | Clinical therapy |
| Country Of Origin | Canada |
| Strength | 2 mg |
| Active Ingredient | Tesamorelin acetate |
| Drug Class | Growth hormone releasing hormone analogue |
| Product Type | Injectable peptide |
| Molecular Weight | 5135 Da |
| Primary Function | Stimulates HGH secretion |
| Mechanism | Activates GHRH receptors |
| Target System | Endocrine system |
| Administration | Subcutaneous injection |
| Dosage Form | Injectable solution |
| Frequency | Daily injection |
| Formulation | Prefilled syringe or vial |
| Storage | 2–8°C |
| Shelf Life | 24 months |
| Packaging | Sterile injection vial |
| Appearance | Clear or lyophilized powder |
| Stability | Sensitive to heat |
| Application | Clinical therapy |
| Country Of Origin | Canada |
3316 E Richert AveFresno, CA 93726, USA
GET DIRECTION